COL14127-showcase
An estimated 48.5 million couples suffer from infertility worldwide (1), driving up usage of assisted reproductive technologies around the globe. As a result, preimplantation genetic testing (PGT), has become commonplace in vitro fertilization (IVF) research, to evaluate the status of an embryo.

Commonly used PGT testing solutions:

  • Preimplantation genetic testing-aneuploidy (PGT-A): detects aneuploidies, or chromosomal abnormalities, across all 24 chromosomes (22 autosomes and the X and Y chromosomes)
  • Preimplantation genetic testing-monogenic (PGT-M): identifies specific genetic variants in a single gene associated with known predisposition within the family

Advancements in next-generation sequencing (NGS) methods enable simple, scalable, and innovative sample-to-answer workflow solutions for PGT-A and PGT-M. NGS delivers fast results from precious samples, without the complexities that come with traditional genetic analysis tools.

Hear what your peers are saying about NGS and preimplantation genetic testing:

Webinar: The benefits of PGT-A, PGT-M and expanded carrier screening in IVF research

Follow the decision-making process and adoption of expanded carrier screening (ECS) and preimplantation genetic testing (PGT-A (aneuploidy) and PGT-M (monogenic)) in patient care and reproductive genetics research labs.

Follow the decision-making process and adoption of expanded carrier screening (ECS) and preimplantation genetic testing (PGT-A (aneuploidy) and PGT-M (monogenic)) in patient care and reproductive genetics research labs.

Two presentations, followed by combined Q&A, cover:

  • Importance of preconception testing and advantages of NGS technology
  • Research data demonstrating:
    • Carrier screening capabilities and influence on family planning
    • Impact of PGT-A on pregnancy success rates
    • Advantages of PGT-M over alternative approaches

Dr Murat Cetinkaya, PhD
Istanbul Memorial Hospital Assisted Reproductive Technologies and Reproductive Genetic Center

Prof Volkan Baltaci, MD, PhD
CEO, Mikrogen Reproductive Genetics Company